Gri Bio Etf Performance
| GRI Etf | USD 0.74 0.05 7.25% |
The etf retains a Market Volatility (i.e., Beta) of -1.5, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GRI Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, GRI Bio is expected to outperform it.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in GRI Bio are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, GRI Bio demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:13 | Last Split Date 2024-06-18 |
1 | GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/05/2024 |
2 | GRI Bio to Participate in a Virtual Investor CEO Connect Segment | 09/25/2024 |
3 | GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis | 10/07/2024 |
4 | GRI Bio Raises a Total of 13.9 Million in Gross Proceeds Since the Beginning of 2024 | 10/24/2024 |
5 | GRI Bio Showcases GRI-0621s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis | 11/21/2024 |
| Begin Period Cash Flow | 9000.00 |
GRI |
GRI Bio Relative Risk vs. Return Landscape
If you would invest 53.00 in GRI Bio on August 28, 2024 and sell it today you would earn a total of 21.00 from holding GRI Bio or generate 39.62% return on investment over 90 days. GRI Bio is generating 1.7682% of daily returns assuming volatility of 19.1535% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than GRI, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
GRI Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GRI Bio's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as GRI Bio, and traders can use it to determine the average amount a GRI Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0923
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | GRI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.15 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.77 actual daily | 35 65% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average GRI Bio is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GRI Bio by adding it to a well-diversified portfolio.
GRI Bio Fundamentals Growth
GRI Etf prices reflect investors' perceptions of the future prospects and financial health of GRI Bio, and GRI Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GRI Etf performance.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 1.54 M | ||||
| Shares Outstanding | 8.93 M | ||||
| Price To Earning | 23.35 X | ||||
| Price To Book | 1.68 X | ||||
| Revenue | 21.77 M | ||||
| EBITDA | (10.9 M) | ||||
| Cash And Equivalents | 183.82 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 14 K | ||||
| Debt To Equity | 1.23 % | ||||
| Book Value Per Share | 5.21 X | ||||
| Cash Flow From Operations | (9.14 M) | ||||
| Earnings Per Share | 77.53 X | ||||
| Total Asset | 2.96 M | ||||
| Retained Earnings | (31.53 M) | ||||
| Current Asset | 1.22 B | ||||
| Current Liabilities | 243.82 M | ||||
About GRI Bio Performance
By evaluating GRI Bio's fundamental ratios, stakeholders can gain valuable insights into GRI Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GRI Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GRI Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA.| GRI Bio is way too risky over 90 days horizon | |
| GRI Bio has some characteristics of a very speculative penny stock | |
| GRI Bio appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 21.77 M. Reported Net Loss for the year was (13.04 M) with profit before taxes, overhead, and interest of 0. | |
| GRI Bio has about 183.82 M in cash with (9.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Latest headline from globenewswire.com: GRI Bio Showcases GRI-0621s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis | |
| The fund retains 99.63% of its assets under management (AUM) in equities |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.